Division of Gynecologic Oncology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
Curr Treat Options Oncol. 2019 Nov 21;20(11):83. doi: 10.1007/s11864-019-0679-5.
Among gynecologic malignancies, mismatch repair-deficient endometrial cancers show the greatest response to anti-programmed cell death-1 (PD-1) antibodies, such as pembrolizumab. Routine immunohistochemical (IHC) and molecular testing should be performed on all endometrial cancers at the time of diagnosis in order to identify endometrial cancers with mismatch repair deficiency that may show improved response to anti-PD-1 therapy in the progressive or metastatic setting. Institutional effort to enroll patients in clinical trials investigating the use of immune checkpoint inhibitors in endometrial cancer should be prioritized.
在妇科恶性肿瘤中，错配修复缺陷型子宫内膜癌对程序性细胞死亡蛋白 1（PD-1）抗体（如 pembrolizumab）的反应最为显著。所有子宫内膜癌在诊断时都应进行常规免疫组织化学（IHC）和分子检测，以识别可能对进展期或转移性环境中的抗 PD-1 治疗有更好反应的错配修复缺陷型子宫内膜癌。应优先优先考虑机构努力将患者纳入临床试验，以研究免疫检查点抑制剂在子宫内膜癌中的应用。
